Revenue distribution by industry:

• Ostomy care: approx. 40%
• Continence care: approx. 30%
• Wound care: approx. 20%
• Urology and others: approx. 10%

TOP 3 markets and their percentage shares:

• USA: approx. 35%
• Germany: approx. 20%
• France: approx. 15%

Coloplast A/S generates the majority of its revenue from ostomy care and continence care, which is due to the strong demand in these areas. The USA is the largest market for Coloplast, followed by Germany and France, highlighting the importance of the European market for the company. These markets benefit from an aging population and increased health awareness, which boosts the demand for Coloplast's medical products.

Production sites of Coloplast A/S:

1. Denmark
2. Hungary
3. China
4. France
5. Costa Rica

Coloplast A/S is a globally operating company specializing in the production of medical products. The production facilities are strategically located in different countries to optimize both proximity to markets and production efficiency. Denmark, as the company's home country, plays a central role, while Hungary and China are important sites for production in Europe and Asia. Costa Rica serves as an important location for serving the American market.

Revenue Growth: Estimated at 8-10% annually (based on historical trends until 2023)
Focus on Innovation: Investments in research and development, approximately 3-4% of revenue
Market Expansion: Increased presence in emerging markets

Coloplast A/S pursues a growth strategy that heavily emphasizes innovation and market expansion. The company consistently invests in research and development to develop innovative products that better meet the needs of patients. These investments account for about 3-4% of revenue, indicating a strong commitment in this area.

In addition, Coloplast places great importance on expanding into emerging markets, which offer significant growth potential. By expanding distribution networks and adapting product ranges to local needs, the company aims to increase its market share in these regions.

Another component of the strategy is to enhance operational efficiency to increase profitability while simultaneously improving customer loyalty through top-notch service and support.

Main raw materials: Plastic, silicone, cellulose

Main supplying countries: Germany, USA, China

Coloplast A/S is a leading company in the healthcare sector that manufactures products for stoma care, continence care, wound care, and skin care. The main raw materials imported by Coloplast include plastics, silicone, and cellulose, which are essential for the production of their medical products.

Germany and the USA are important suppliers of high-quality plastics and silicone used in the production of medical devices and aids. China is a significant supplier of raw materials and semi-finished products that can be cost-effectively integrated into the production processes.

By diversifying their supply chains, Coloplast ensures that they can source the necessary materials in high quality and at competitive prices, which is crucial for maintaining their market position.

Market share in the field of stoma care: approximately 40% (2024)

Market share in the field of continence care: approximately 35% (2024)

Coloplast A/S has a significant competitive advantage, especially in the areas of stoma care and continence care, where the company holds leading market shares. This strong market position is supported by continuous innovations and a broad product portfolio.

The company benefits from high barriers to entry in the industry, characterized by regulatory requirements and the need for specialized technical expertise. Furthermore, Coloplast strengthens its market position through strategic partnerships and a strong global presence.

Another competitive advantage arises from close collaboration with healthcare providers and patients, leading to high customer satisfaction and brand loyalty. This enables Coloplast to continuously adapt its products to meet user needs and maintain its market leadership.

Institutional Investor Share: 45% (estimated 2025)
Insider Buys/Sells: No significant transactions in the last year (2024)

The institutional investor share in Coloplast A/S is estimated to be around 45%. This indicates that a significant portion of the shares are held by large financial institutions, suggesting a certain level of trust in the company's long-term stability and growth potential.

In 2024, there were no significant insider buys or sells, indicating that the management and other insiders do not expect significant changes in their assessment of the company's value. This can be seen as a sign of stable corporate governance and a balanced outlook on future business development.

Market share of Coloplast A/S: 32% (estimated for 2025)

Top competitors and their market shares:

1. Coloplast A/S: 32%
2. ConvaTec Group: 20%
3. Hollister Incorporated: 15%
4. B. Braun Melsungen AG: 12%
5. Medtronic: 8%
6. Smith & Nephew: 5%
7. 3M Healthcare: 4%
8. Molnlycke Health Care: 3%
9. Paul Hartmann AG: 1%

Coloplast A/S holds a significant market share in the field of medical products, especially in stoma and wound care. The company's moat mainly lies in its strong brand recognition, high product quality, and close collaboration with medical professionals. These factors enable Coloplast to maintain a leading position and stand out from the competition.

Compared to its competitors, Coloplast has a solid moat supported by continuous innovations and strong customer loyalty. ConvaTec and Hollister are also strong competitors with their own advantages, such as specialized product lines and global distribution networks. However, Coloplast remains in an advantageous position due to its comprehensive product range and innovative capabilities.

The competition is fierce, but Coloplast has a sustainable advantage through strategic investments in research and development and expanding its market presence, allowing the company to maintain its market leadership.

Revenue growth: 7.5% (2024) EBIT margin: 31.2% (2024) Research & Development (R&D) expenses: 5.8% of revenue (2024)

Coloplast A/S achieved a revenue growth of 7.5% in 2024, driven by strong demand for their healthcare products. The EBIT margin of 31.2% demonstrates high profitability and efficiency in operations, which is attractive to investors.

The company continues to heavily invest in research and development, with expenses amounting to 5.8% of revenue. This indicates Coloplast's commitment to developing innovative products and strengthening its market position.

Given these metrics and Coloplast's stable market position, the stock could be an attractive investment for investors interested in long-term growth. The ongoing investments in R&D and the strong operational margin support sustainable business development.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Continuous payout over the last 10 years

Coloplast A/S is known for its reliable dividend policy. The company has consistently distributed dividends in recent years, indicating stable financial performance and a solid business model. The dividend yield for 2025 is estimated to be around 2.5%, which is competitive compared to other companies in the industry.

The reliability of Coloplast's dividend payments is supported by its strong market position and continuous demand for its products. The company has a solid balance sheet and regularly generates positive cash flows, further substantiating its ability to pay dividends.